Security
Amplitude Healthcare Acquisition Corporation Unit · AMHCU
AMHCUNASDAQUnitHistorical · closed Sep 24, 2021CIK 1788028Updated Nov 10, 2026
Name history
Amplitude Healthcare Acquisition Corp · through Sep 29, 2021
Current security for this SEC filerJSPR · NASDAQ
AMHCU price & chart
Historical security
This listing closed Sep 24, 2021. Live provider charts are shown only for current listings.
Current security: JSPR
About the company
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including vensobafusp alfa, briquilimab, and KP701. Vensobafusp alfa is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant in severe combined immunodeficiencies (SCID), Fanconi anemia, as well as mast cell mediated diseases such as the chronic urticarias. KP701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
SCHEDULE 13G - filed by BANK OF AMERICA CORP /DE/ regarding Jasper Therapeutics, Inc.
SC TO-I/A - filed by Jasper Therapeutics, Inc. regarding Jasper Therapeutics, Inc.
DEF 14A filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
S-3 filing
PRE 14A filing
Other Events
Items 8.01, 9.01
SC TO-I - filed by Jasper Therapeutics, Inc. regarding Jasper Therapeutics, Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 57,469,000Source | 99,413,000Source | 11,802,000Source | 46,466,000Source | 113,929,000Source | 21,184,000Source | 57,597,000Source | 125,963,000Source | 35,779,000Source | 79,899,000Source | 94,892,000Source | 48,361,000Source |
| Property, Plant and Equipment, NetUSD | 1,102,000Source | 2,071,000Source | 60,000Source | 1,331,000Source | 2,438,000Source | 81,000Source | 1,599,000Source | 2,464,000Source | 102,000Source | 1,875,000Source | 2,727,000Source | 3,568,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 50,899,000Source | 92,502,000Source | 7,314,000Source | 39,510,000Source | 106,819,000Source | 14,144,000Source | 48,799,000Source | 118,475,000Source | 28,692,000Source | 71,637,000Source | 86,887,000Source | 38,250,000Source |
| Assets, CurrentUSD | 54,564,000Source | 94,806,000Source | 11,571,000Source | 42,966,000Source | 108,680,000Source | 20,292,000Source | 53,174,000Source | 120,308,000Source | 34,645,000Source | 75,811,000Source | 88,938,000Source | 41,731,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,665,000Source | 2,304,000Source | 3,840,000Source | 3,456,000Source | 1,861,000Source | 6,148,000Source | 4,375,000Source | 1,833,000Source | 5,953,000Source | 4,174,000Source | 2,051,000Source | 2,818,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,236,000Source | 1,106,000Source | 128,000Source | 1,560,000Source | 1,231,000Source | 317,000Source | 1,875,000Source | 1,351,000Source | 502,000Source | 976,000Source | 1,467,000Source | 1,886,000Source |
| Other Assets, NoncurrentUSD | 150,000Source | 1,013,000Source | 43,000Source | 192,000Source | 1,163,000Source | 77,000Source | 532,000Source | 1,423,000Source | 113,000Source | 820,000Source | 1,343,000Source | 759,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 45,898,000Source | 15,733,000Source | 10,389,000Source | 22,965,000Source | 13,619,000Source | 17,784,000Source | 15,353,000Source | 12,733,000Source | 31,628,000Source | 18,225,000Source | 16,452,000Source | 12,372,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 3,000Source | 2,000Source | 1,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 319,137,000Source | 300,226,000Source | 322,014,000Source | 312,332,000Source | 298,219,000Source | 321,241,000Source | 304,352,000Source | 296,556,000Source | 320,818,000Source | 302,541,000Source | 248,039,000Source | 141,120,000Source |
| Retained Earnings (Accumulated Deficit)USD | -307,569,000Source | -216,548,000Source | -320,604,000Source | -288,833,000Source | -197,911,000Source | -317,844,000Source | -262,110,000Source | -183,328,000Source | -316,670,000Source | -240,869,000Source | -169,600,000Source | -105,135,000Source |
| Stockholders' Equity Attributable to ParentUSD | 11,571,000Source | 83,680,000Source | 1,413,000Source | 23,501,000Source | 100,310,000Source | 3,400,000Source | 42,244,000Source | 113,230,000Source | 4,151,000Source | 61,674,000Source | 78,440,000Source | 35,989,000Source |
| Liabilities and EquityUSD | 57,469,000Source | 99,413,000Source | 11,802,000Source | 46,466,000Source | 113,929,000Source | 21,184,000Source | 57,597,000Source | 125,963,000Source | 35,779,000Source | 79,899,000Source | 94,892,000Source | 48,361,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 21,041,000Source | 12,459,000Source | 7,845,000Source | 20,500,000Source | 10,068,000Source | 8,996,000Source | 12,334,000Source | 8,916,000Source | 13,200,000Source | 15,237,000Source | 12,374,000Source | 7,065,000Source |
| Operating Lease, Liability, CurrentUSD | 1,703,000Source | 1,059,000Source | 270,000Source | 1,954,000Source | 1,029,000Source | 757,000Source | 1,835,000Source | 1,000,000Source | 1,235,000Source | 1,089,000Source | 972,000Source | 865,000Source |
| Accounts Payable, CurrentUSD | 9,166,000Source | 3,086,000Source | 2,778,000Source | 8,034,000Source | 2,964,000Source | 2,439,000Source | 2,995,000Source | 2,391,000Source | 6,220,000Source | 4,027,000Source | 4,149,000Source | 1,768,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 1,010,000Source | — | 201,000Source | 1,287,000Source | — | 755,000Source | 1,553,000Source | — | 724,000Source | 1,814,000Source | 2,786,000Source |
| Other Liabilities, NoncurrentUSD | 2,264,000Source | 2,264,000Source | — | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,353,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 37,700,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 21,000Source | 279,000Source | 1,056,000Source | 1,373,000Source | 1,108,000Source | 1,000,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 423,000Source | 1,811,000Source | 6,713,000Source | 6,619,000Source | 5,211,000Source | 4,091,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -3,781,000Source | -1,039,000Source | 2,193,000Source | -122,000Source | 2,381,000Source | -2,151,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -14,548,000Source | -22,842,000Source | -77,161,000Source | -62,602,000Source | -52,067,000Source | -45,858,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 4,000Source | 5,000Source | -532,000Source | -267,000Source | -576,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | 960,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 34,211,000Source | 47,884,000Source | 100,971,000Source | 55,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 51,316,000Source | 92,919,000Source | 7,731,000Source | 39,927,000Source | 14,561,000Source | 49,216,000Source | 29,109,000Source | 72,054,000Source | 87,304,000Source | 38,667,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,424,000Source | 1,998,000Source | — | — | — | 1,811,000Source | — | 6,619,000Source | — | — |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 327,000Source | — | — |
| Equipment ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,706,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -11,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 4,775,000Source | 5,434,000Source | 4,072,000Source | 5,880,000Source | 5,138,000Source | 5,645,000Source | 20,779,000Source | 20,418,000Source | 17,076,000Source | 16,569,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 2,000Source | — | — |
| Investment Income, InterestUSD | — | — | 342,000Source | 1,284,000Source | 82,000Source | 437,000Source | 164,000Source | 624,000Source | 1,741,000Source | 5,058,000Source | 5,199,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,736,000Source | -18,637,000Source | -2,760,000Source | -26,723,000Source | -1,174,000Source | -21,241,000Source | -75,801,000Source | -71,269,000Source | -64,465,000Source | -37,685,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | -26,723,000Source | — | -21,241,000Source | — | -71,269,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 430,000Source | 1,252,000Source | 6,447,000Source | 353,000Source | 9,778,000Source | 561,000Source | 8,082,000Source | 4,970,000Source | — | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,200,000Source |
| Operating ExpensesUSD | — | — | 19,166,000Source | 19,889,000Source | 9,207,000Source | 27,076,000Source | 10,952,000Source | 21,802,000Source | 83,883,000Source | 76,239,000Source | 68,861,000Source | 51,196,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 400,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -2,011,000Source | -32,000Source | 2,385,000Source | -84,000Source | -26,000Source | -63,000Source | -2,187,000Source | -88,000Source | — | 586,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 6,500,000Source | — | 6,454,000Source | 47,195,000Source | — | 28,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 329,000Source | 388,000Source | 27,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | 2,253,000Source | — | — | — |
| Depreciation | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — |
| Operating Income (Loss)USD | — | — | -19,166,000Source | -19,889,000Source | -9,207,000Source | -27,076,000Source | -10,952,000Source | -21,802,000Source | -83,883,000Source | -76,239,000Source | -68,861,000Source | -51,196,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,011,000Source | -32,000Source | 2,385,000Source | -84,000Source | -26,000Source | -63,000Source | -2,187,000Source | -88,000Source | — | 586,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 2,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,736,000Source | -18,637,000Source | -2,760,000Source | -26,723,000Source | -1,174,000Source | -21,241,000Source | -75,801,000Source | -71,269,000Source | -64,465,000Source | -37,685,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.13Source | -1.24Source | -0.1Source | -1.74Source | -0.04Source | -1.41Source | -3.95Source | -4.89Source | -6.18Source | -1.03Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.13Source | -1.24Source | -0.1Source | -1.74Source | -0.04Source | -1.41Source | -3.95Source | -4.89Source | -6.18Source | -1.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 16,635,784Source | 15,000,516Source | 28,696,937Source | 15,333,962Source | 28,671,819Source | 15,022,122Source | 19,168,110Source | 14,584,870Source | 10,439,034Source | 36,482,761Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 16,635,784Source | 15,000,516Source | 28,696,937Source | 15,333,962Source | 28,671,819Source | 15,022,122Source | 19,168,110Source | 14,584,870Source | 10,439,034Source | 36,482,761Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 21,000Source | 279,000Source | 1,056,000Source | 1,373,000Source | — | 975,000Source |
| Equipment ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,706,000Source |
| General and Administrative ExpenseUSD | — | — | 4,775,000Source | 5,434,000Source | 4,072,000Source | 5,880,000Source | 5,138,000Source | 5,645,000Source | 20,779,000Source | 20,418,000Source | 17,076,000Source | 16,569,000Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | -246,000Source | — |
| Investment Income, InterestUSD | — | — | 342,000Source | 1,284,000Source | 82,000Source | 437,000Source | 164,000Source | 624,000Source | 1,741,000Source | 5,058,000Source | 5,199,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | -26,723,000Source | — | -21,241,000Source | — | -71,269,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 430,000Source | 1,252,000Source | 6,447,000Source | 353,000Source | 9,778,000Source | 561,000Source | 8,082,000Source | 4,970,000Source | — | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,200,000Source |
| Operating ExpensesUSD | — | — | 19,166,000Source | 19,889,000Source | 9,207,000Source | 27,076,000Source | 10,952,000Source | 21,802,000Source | 83,883,000Source | 76,239,000Source | 68,861,000Source | 51,196,000Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | 4,396,000Source | 13,511,000Source |
| Research and Development ExpenseUSD | — | — | 14,391,000Source | 14,455,000Source | 5,135,000Source | 21,196,000Source | 5,814,000Source | 16,157,000Source | 63,104,000Source | 55,821,000Source | 51,785,000Source | 34,627,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | 2,253,000Source | — | — | — |
Offerings
Registration 333-299459
Filing attachments
ea031143301ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 JASPER THERAPEUTICS, INC. ANNOUNCES RESULTS OF THE THE OFFER TO PURCHASE RELATING TO ITS WARRANTS REDWOOD CITY, Calif., November 9, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the results of its offer to purchase (the “Offer”) all of its outstanding warrants to purchase shares of i…
Read attachment ↗ea030997801ex99-1.htm · 8-K · 2026-11-04
Exhibit 99.1 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced a 1-for-30 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”) that will become effective at 12:01 a.m. Eastern T…
Read attachment ↗ea030865701ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, Calif., October 15, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), …
Read attachment ↗ea030792501ex99-1.htm · 8-K · 2026-10-07
Exhibit 99.1 Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants REDWOOD CITY, Calif., October 7, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the “Offer”) any and all of its outstanding warrants to purchase shares of …
Read attachment ↗ea030686001ex99-1.htm · 8-K/A · 2026-10-01
Exhibit 99.1 KIRA PHARMACEUTICALS INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Independent Auditors’ Report F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations and Comprehensive Loss F-5 Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit F-6 Co…
Read attachment ↗ea030686001ex99-2.htm · 8-K/A · 2026-10-01
Exhibit 99.2 KIRA PHARMACEUTICALS INDEX TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets F-2 Condensed Consolidated Statements of Operations and Comprehensive Loss F-3 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit F-4 Condensed Consolidated Statements of Cash Flows …
Read attachment ↗